Author: admin

Streaming Hits Like ‘Love Island,’ ‘Squid Game’ Are Squashing Broadcast TV

Topline

A pair of record-breaking television shows on Netflix and NBC’s Peacock drove streaming to account for nearly 50% of all television usage in June and pushed traditional broadcast viewing to its lowest-ever share of TV use, despite airing the NBA Finals and several top-rated evening news broadcasts.

Olandria Carthen, Amaya Espinal, Chris Seeley, Iris Kendall and Nicolas “Nic” Vansteenberghe on … More “Love Island.”

Kim Nunneley/Peacock via Getty Images

Key Facts

Streaming accounted for 46% of all TV use in June, up 5.4% from May, and both Netflix and Peacock saw viewership jump 13.5% and 13.4%, respectively, from May to June, new Nielsen numbers show.

Netflix can spread the love around—its surge was thanks to a number of hit originals and acquired shows—while Peacock has just one show to thank: “Love Island,” which hit a new high in popularity in its seventh season to become the platform’s most-watched entertainment series of all time.

“Love Island,” which aired its anticipated finale over the weekend, was still streamed for 4.4 billion viewing minutes last month.

On Netflix, the third season release of “Ginny & Georgia” made the show the most-streamed title of the month with 8.7 billion viewing minutes, followed by acquired series “Animal Kingdom” and “Blindspot” (5.71 billion and 5.69 billion minutes, respectively) and the final season of “Squid Game,” which didn’t debut until the end of the month but notched nearly a billion viewing minutes per day in the final three days of June.

”Squid Game” broke the Netflix three-day streaming record with 60.1 million views in the period and became the first-ever show ranked No. 1 in its first week in all 93 countries where Netflix has a Top 10.

“Squid Game” was the most-watched streaming original series of the first half of the year, Nielsen data released Monday showed, followed by Prime Video’s “Reacher” and “The Night Agent” and “Ginny & Georgia” on Netflix.

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here: joinsubtext.com/forbes.

Big Number

19. That’s where “Love Island” falls on Nielsen’s list of most-watched original streaming content for the year so far.

Tangent

It’s not unusual for there to be a summer lull in viewing for traditional broadcast and cable viewing, but June brought the worst-ever month for broadcast television. Broadcast viewing was down 5% from May to represent just 18.5% of total TV, marking the first time ever the category has fallen below a 20% share despite a small boost from the NBA finals. Things weren’t as dark for cable, which stayed fairly flat compared to May and finished June with a 23.4% share of television. The NBA Conference Finals on ESPN and TNT ranked as the top two cable telecasts and cable news viewing was up 12% over May. Special programming also helped bring viewers including the Army 250 Parade on FOX News, which ranked fifth among cable programs with 2.8 million viewers, and a live airing of Broadway’s “Goodnight and Good Luck” on CNN, which was seventh among cable programs in June with 2.4 million viewers.

Surprising Fact

“Bluey,” a children’s cartoon, was the most-watched show across all of streaming in the first half of 2025. The show was streamed on Disney+ for more than 25 billion minutes from Dec. 29, 2024 to June 28, 2025. “Grey’s Anatomy” was the second most popular (22.6 billion minutes viewed), followed by “NCIS” (19.1 billion), “Family Guy” (19 billion) and “Bob’s Burgers” (17.1 billion).

Further Reading

Forbes‘Bluey’ Outranks Streaming’s Most Popular Originals—Including ‘Squid Game’By Mary Whitfill RoeloffsForbes‘Love Island USA’ Season 7: Who Won And Which Couples Are Still Together?By Monica MercuriForbes‘Squid Game’ Smashes Netflix Records: No. 1 In 93 CountriesBy Mary Whitfill Roeloffs

Continue Reading

July 15, 2025
Defending champion Sabalenka tops Cincinnati entry list

Another incredible field is lined up for the Cincinnati Open, the second WTA 1000 event of this year’s North American summer hard-court swing.

Using the PIF WTA Rankings dated June 30 (pre-Wimbledon), the Top 65 players have been entered in the main-draw field, which was released before the Wimbledon final last week.

This is the first year of the expanded Cincinnati Open. Like the Montreal event which precedes it, Cincinnati’s draw will expand from 56 players to a 96-player size.

Main-draw action in Cincinnati will also take place over 12 days. The main-draw matches will start on Thursday, August 7 and conclude with a Monday final on August 18.

World No. 1 Aryna Sabalenka and defending champion Aryna Sabalenka is naturally at the top of the entries. Sabalenka won her sixth career WTA 1000 title here last year — since then, she has added three more.

All of this year’s Grand Slam champions will also be in attendance — Australian Open champion Madison Keys, Roland Garros winner Coco Gauff, and the recently-crowned Wimbledon titlist, Iga Swiatek.

Six players have entered the main draw with their protected rankings, including Grand Slam champions Petra Kvitova, Marketa Vondrousova and Bianca Andreescu.

Former Cincinnati champions in the main-draw entries are Keys (2019), Gauff (2023), and Sabalenka (2024). Two other former champions, Victoria Azarenka (2013, 2020) and Caroline Garcia (2022) are currently entered in qualifying.

“We look forward to welcoming the world’s best tennis stars to compete for the Cincinnati Open title in August,” Tournament Director Bob Moran stated. “We have received a lot of excitement from the players about coming back to see our transformed campus and experiencing the new player amenities. Players and fans alike will enjoy the re-imagined venue and world-class atmosphere as the sport’s best compete for the title.”

You can find the player field on the Cincinnati Open website here!

Continue Reading

July 15, 2025
Lottie Woad Turns Professional, Accepts LPGA Tour Membership | News | LPGA | Ladies Professional Golf Association – LPGA
1. Lottie Woad Turns Professional, Accepts LPGA Tour Membership | News | LPGA | Ladies Professional Golf Association LPGA
2. In Good Graces: Australia’s Kim Becomes First-Time Major Winner at The Amundi Evian Championship LPGA
3. Amateur phenom earns LPGA card in thrilling, historic fashion GOLF.com
4. Lottie Woad has turned professional The Golf Business
5. Top amateur Lottie Woad will make pro debut at next week’s Scottish Open Golfweek
Continue Reading
July 15, 2025
Readout Newsletter: Kailera, Zepbound, Certara, BioLabs

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We have a short and sweet newsletter today. And if you are in any areas hit by the flash foods, I hope you’re staying safe.

A lab pioneer fears U.S. industry is losing its edge

Johannes Fruehauf, founder of laboratory real estate companies LabCentral and BioLabs, is increasingly looking to Europe — and even Saudi Arabia — as U.S. policies cloud the future of biotech stateside.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Continue Reading

July 15, 2025
Field Marshal Munir, Indonesian defence minister discuss strengthening military ties: ISPR – Pakistan

Minister of Defence of Indonesia Lieutenant General (Retd) Sjafrie Sjamsoeddin called on Field Marshal Syed Asim Munir on Tuesday and discussed about enhancing bilateral military ties, the Inter-Services Public Relations (ISPR) said.

Sjamsoeddin, leading a delegation comprising representatives from various services and intelligence agencies, met the chief of army staff at the General Headquarters in Rawalpindi.

The military’s media wing said during the meeting both sides exchanged views on bilateral defence collaboration, regional security dynamics and avenues to further strengthen military ties.

Pakistan, Russia agree to enhance ties in trade, energy, defence sectors

“The meeting underscored the longstanding friendship and cooperation between the two countries. The field marshal highlighted the importance of mutual cooperation in maintaining peace and stability in the region,” the ISPR said.

On this occasion, the Indonesian defence minister appreciated the role of Pakistan Army in fight against terrorism and reaffirmed Indonesia’s commitment to enhancing defence relations with Pakistan.

Earlier, the Indonesian delegation, led by Defence Minister Sjamsoeddin, called on Prime Minister Shehbaz Sharif in Islamabad on Tuesday.

During the meeting, PM Shehbaz reaffirmed Pakistan’s commitment to explore and expand collaboration with Indonesia in joint ventures of investment in mutually beneficial projects.

Minister of Defence of Indonesia Lieutenant General (Retd) Sjafrie Sjamsoeddin in a meeting with PM Shehbaz Sharif in Islamabad on July 15, 2025. Photo: Radio Pakistan

The meeting underscored the deep-rooted historical, brotherly and friendly bilateral relations between Pakistan and Indonesia.

The prime minister, while recalling his cordial meeting with Indonesian President Prabowo Subiantuo on the sidelines of G-8 Summit in Cairo, Egypt, conveyed his best wishes for the Indonesian president.

He said Pakistan and Indonesia enjoy long standing friendship rooted in shared cultural, religious and historical bonds. He said both the countries support each other at international forums.

Shehbaz reiterated Pakistan’s commitment to enhance bilateral cooperation with Indonesia in all avenues including economic, strategic, trade sectors and in the field of defence and defence production.

During the meeting, the two sides emphasised on the importance of enhancing multi-faceted bilateral cooperation.

The premier also reviewed ongoing initiatives under the Pakistan-Indonesia Defence Cooperation Agreement and agreed to accelerate implementation of key areas of mutual interest.

On the occasion, the Indonesian defence minister conveyed best wishes of Indonesian President Subiantro for the prime minister and people of Pakistan.

He reiterated Indonesia’s desire to further strengthen defence ties with Pakistan and to explore possible areas for cooperation, especially in defence production.

Continue Reading

July 15, 2025
The Habitable Worlds Observatory Could Find More Very Massive Stars

Very massive stars (VMSs)have had a massive impact on the formation of our universe. However, there aren’t very many of them, with only around 20 known specimens in the Milky Way and Large Magellanic Cloud. Even observing those is difficult for the current generation of telescopes, which is where an unexpected technological champion might play a role. According to a new paper by Fabrice Martins of CNRS and a group of European and American researchers, the upcoming Habitable World Observatory (HWO) might be our most useful tool when it comes to finding these elusive giants.

VMSs are typically huge, around hundreds of times the size of our Sun. As such, they are much brighter than a typical star, and have much higher mass loss rates, making them prime candidates to have seeded the local galactic area with “metals”, anything other than hydrogen and make up a large amount of the building blocks of all planets, asteroids and moons. However, they also are typically found in star clusters where they are surrounded by dozens or hundreds of other, normal stars.

To find these (admittedly very large) needles in the haystack of these clusters, a telescope would need extremely high spectral resolution, and that is exactly what the HWO provides. With an angular resolution of around 5 milli-arc-seconds (mas), it would be possible to resolve individual stars in most of the clusters where the VMSs reside, most of which would require between .5 to 110 mas.

However, it’s not enough to resolve individual stars – it’s important to confirm the star itself is “very massive”, as opposed to normal sized, or even just “massive”. The “very” in the name isn’t just hyperbole, it actually signifies a different physical process that these stars undergo, making that distinction important.

Fraser talks about the biggest star in the universe.

To differentiate between the types of very large stars, astronomers will look at the individual star’s optical and UV spectra. This is another area where the HWO has an advantage – ground-based telescopes might have the resolution to resolve these individual stars, but they lack the ability to see in UV due to it being blocked by our atmosphere.

There are several spectral features astronomers will distinguish, including spectral lines around HeII 4686 (that’s the helium-2 spectral line at 4686 Angstroms, not a name intended to scare astronomers away from studying it) and CIV 5801-12, which is emitted by a triply ionized carbon atom and is clearly defined at two different spectrum line – 5801 and 5012 Angstroms. Each of those lines help differentiate between a VMS and a Wolf-Rayet star, another type of massive star that is a descendant of the truly massive stars astronomers are looking for.

Ultimately what astronomers are looking for is a bound on the speed of mass loss in these stars compared to their metallicity. That map would help inform galactic evolution models, and show how things like planets and even other, smaller stars take shape. However, VMSs only exist for a few million years before they either collapse into a black hole or explode into a supernova. Given their relatively short lifetime, rarity, and importance to the evolution of both planets and stars, astronomers are hopeful they’ll be able to collect plenty more data about these critical stars, even if they have to wait until at least the early 2040s, which is the earliest HWO could potentially launch if it clears all the hurdles put into place before then.

Dr. Becky talks about the capabilities of the HWO.

Learn More:

F. Martins et al – Very Massive Stars with the Habitable Worlds Observatory

UT – Very Massive Stars Expel More Matter Than Previously Thought

UT – The Galactic Center Struggles to Form Massive Stars

UT – Giant Cluster is Spitting Out Massive Stars

Continue Reading

July 15, 2025
Tabelecleucel Advances in EBV+ PTLD With Phase 3 Trial and FDA Resubmission
- Pierre Fabre Laboratories has assumed global responsibility for clinical development and manufacturing of tabelecleucel (tab-cel; Ebvallo), including oversight of 2 active clinical trials in Epstein-Barr virus–associated (EBV+) posttransplant lymphoproliferative disorder (PTLD) and EBV-associated diseases.
- Enrollment continues for the pivotal phase 3 ALLELE study (NCT03394365) evaluating tab-cel in patients with relapsed or refractory EBV+ PTLD after solid organ or hematopoietic cell transplantation.
- Atara Biotherapeutics has resubmitted the biologics license application (BLA) for tab-cel following FDA feedback, with potential US approval pending.
Pierre Fabre Pharmaceuticals has officially assumed global clinical development responsibility for tab-cel, an off-the-shelf allogeneic T-cell therapy targeting EBV-infected cells.¹ The company’s new role follows the transfer of the investigational new drug (IND) application from partner Atara Biotherapeutics on July 14, 2025, advancing tab-cel’s development for EBV+ PTLD and related EBV-driven malignancies.

This follows Atara Biotherapeutics’ resubmission of the BLA for tab-cel to the FDA on July 11, 2025. The initial application had received a complete response letter (CRL) in January 2025 due to issues with a third-party manufacturing facility.² There were no issues with regard to efficacy or safety data in the CRL. Further, no additional clinical studies were requested to support the resubmission of the BLA.

“The BLA resubmission for tab-cel represents the collaborative efforts with our partner, Pierre Fabre Laboratories, to address the third-party manufacturing facility observations outlined in the January 2025 CRL,” said Cokey Nguyen, PhD, president and chief executive officer of Atara Biotherapeutics, stated in a press release.¹ “We look forward to continued engagement with the FDA throughout its review and with Pierre Fabre Laboratories as they actively prepare for the potential launch of this innovative therapy in the US.”

3d rendered medically accurate illustration of too many white blood cells due to leukemia: © Sebastian Kaulitzki – stock.adobe.com

EBV+ PTLD is a rare but often fatal complication that arises in patients with compromised immune surveillance due to immunosuppression following transplant. It is marked by unchecked proliferation of EBV-infected B-cells and carries poor outcomes in patients who fail standard therapies. Median survival is reported at approximately 3 weeks in patients who underwent hematopoietic stem cell transplant (HSCT) and just over 4 months in solid organ transplant (SOT) patients after failing rituximab (Rituxan)-based treatment, highlighting the critical need for novel therapies.

Tab-cel is a donor-derived, EBV-specific, cytotoxic T-cell therapy designed to recognize and eliminate EBV-infected cells in immunocompromised patients. Unlike autologous chimeric antigen receptor (CAR) T-cell therapies, tab-cel is an allogeneic therapy produced from healthy donors, avoiding the lengthy and complex manufacturing timeline of patient-specific treatments.

Enrollment is ongoing in the pivotal phase 3 ALLELE trial. The study is evaluating tab-cel in patients with EBV+ PTLD following failure of rituximab or rituximab-based chemotherapy.² This multicenter study includes patients who have undergone either SOT or allogeneic HSCT.

Patients must have biopsy-proven, measurable, FDG-avid EBV+ PTLD with prior failure of rituximab monotherapy or rituximab plus chemotherapy. Key eligibility criteria include adequate organ function, performance status of ≤3 for adults or Lansky score ≥20 for pediatric patients, and confirmed availability of a suitable HLA-partially matched tab-cel product. Central nervous system involvement is permitted if appropriately treated and monitored using Lugano Classification criteria.

The trial’s primary end point is objective response rate (ORR), with secondary end points including duration of response (DOR), complete and partial response rates, time to response, overall survival (OS), and graft-related outcomes in SOT recipients.

Prior results from the phase 3 ALLELE trial support the BLA.⁴ Updated data presented at the 2024 American Society of Hematology Annual Meeting highlighted an ORR of 50.7% among 75 evaluable patients (95% CI, 38.9%–62.4%). Among subgroups, the ORR was 51.0% for SOT recipients and 50.0% for those who had undergone HSCT. The median DOR across the overall cohort was 23 months, with a median OS of 18.4 months.

Importantly, no treatment-related deaths were reported. Serious treatment-emergent adverse events (TEAEs) occurred in 65.4% of HSCT patients and 61.2% of SOT patients, with fatal TEAEs seen in 19.2% and 18.4%, respectively. However, no cases of cytokine release syndrome, infusion reactions, or graft-vs-host disease were observed, underscoring the favorable safety profile of this off-the-shelf therapy.

An additional trial (NCT04554914) is also actively enrolling patients with a broader spectrum of EBV-associated diseases, such as EBV-positive lymphomas beyond PTLD. This multicenter, multicohort, open-label phase 2 study aims to expand the therapeutic potential of tab-cel across various EBV-driven conditions.¹

With both the phase 3 ALLELE and phase 2 EBV-associated disease studies open for enrollment, and a regulatory review process underway in the US, tab-cel is poised to become a key therapeutic option in the management of EBV+ malignancies. Should FDA approval follow the European Commission’s authorization in 2022, oncologists in the US may soon gain access to the first allogeneic T-cell therapy for this ultra-rare and aggressive disease.

REFERENCES
1. Perre Fabre Pharmaceuticals, Inc. announces transfer of investigational new drug application for tabelecleucel from Atara Biotherapeutics, Inc. News release. July 15, 2025. Accessed July 15, 2025. https://tinyurl.com/ynhf9c7a
2. Atara Biotherapeutics provides regulatory and business update on Ebvallo (tabelecleucel). News release. Atara Bihttps://tinyurl.com/ynhf9c7aotherapeutics. January 16, 2025. Accessed July 15, 2025. https://tinyurl.com/yuc4d6jy
3. Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant participants With Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy (ALLELE). ClinicalTrials.gov. Updated July 14, 2025. Accessed July 15, 2025. https://clinicaltrials.gov/study/NCT03394365
4. Updated results of phase 3 ALLELE study presented at 66th American Society of Hematology Annual Meeting confirm efficacy, safety and durability of novel allogeneic cell therapy tabelecleucel in relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). News release. Pierre Fabre Pharmaceuticals. December 7, 2024. Accessed July 15, 2025. https://tinyurl.com/2mauhuw7
Continue Reading
July 15, 2025
BMW M Motorsport News, 15th July 2025.

Björn Lellmann, Head of Customer Racing at BMW M Motorsport:

“In recent weeks, one season highlight followed another. Between the
three major 24-hour races and numerous other motorsport classics
around the world, there was hardly time to catch our breath. We had
many reasons to celebrate and to share great successes with our
customer teams. My congratulations to everyone involved! Most
recently, BMW Italia Ceccato Racing had plenty of reasons to celebrate
with a double podium at Mugello. There were also successes in North
America and Asia. Once again, it’s impressive to see how well our cars
are performing globally. We aim to continue this trend in the second
half of the year.”

—

Italian GT Championship (11th to 13th July): BMW Italia
Ceccato Racing wins at Mugello.

BMW Italia Ceccato Racing triumphed again during the second
sprint weekend of the Italian GT Championship. At Mugello (ITA), BMW M
works drivers Jens Klingmann (GER) and Jesse Krohn (FIN) claimed
victory on Saturday in the #1 BMW M4 GT3 EVO. Behind them, teammates
William Alatalo (FIN) and Leonardo Caglioni (ITA) completed the 1-2
finish for the team led by Roberto Ravaglia (ITA) in the #2 BMW M4 GT3
EVO. For Alatalo and Caglioni, second place overall also meant victory
in the Pro-Am category. After their second win of the season,
Klingmann and Krohn had to serve a pit-stop penalty in Sunday’s race
as per regulations. Despite the 15-second handicap, they secured
another podium by finishing third. Alatalo and Caglioni once again
reached the class podium as second in Pro-Am. In the sprint standings,
Klingmann and Krohn are within striking distance of the leaders,
trailing by just two points after two of four race weekends. “We can
be very proud of the first half of the season,” Klingmann said after
the Mugello weekend. “With the win on Saturday and third place on
Sunday, we came close to a maximum points haul and are very
optimistic. Our mission to defend the title is clearly defined, so we
need to maintain this level of performance, as the field is extremely
competitive this year. But so far, we’re proud and satisfied, having
made no mistakes. We’re looking forward to the second half of the
season with great anticipation.” The next sprint races of the Italian
GT Championship will take place at the end of September at Imola (ITA).

—

IMSA CTMP (11th to 13th July): Pole debut for Verhagen.

BMW M works driver Neil Verhagen (USA) celebrated the first pole
position of his IMSA WeatherTech SportsCar Championship career at
Canadian Tire Motorsport Park (CAN).
“It’s phenomenal. I gave it
everything I had, and it just all came together. It was one of those
laps where everything felt perfect. I can’t thank Paul Miller Racing
and BMW M Motorsport enough for giving me a car that made this
possible. I’m overjoyed with my first pole,” said the 24-year-old
after Saturday’s qualifying. In the GTD-PRO category race, Verhagen
and his compatriot Madison Snow finished sixth in the #1 BMW M4 GT3
EVO of Paul Miller Racing. Their teammates, BMW M works drivers Dan
Harper (GBR) and Max Hesse (GER), brought the #48 BMW M4 GT3 EVO home
in ninth place. In the GTD class, Turner Motorsport finished eighth.

—

IMSA Michelin Pilot Challenge (11th to 13th July): BMW M
Motorsport shines at Mosport.

BMW M Motorsport dominated the IMSA Michelin Pilot Challenge at
Canadian Tire Motorsport Park. Jeff Westphal and Sean McAlister (both
USA) won the race for CarBahn with Peregrine Racing in the #39 BMW M4
GT4 EVO. They were followed by fellow BMW drivers Austin Krainz (USA)
and Steven McAleer (GBR) in the #27 BMW M4 GT4 EVO from Auto Technic
Racing, who took second place. Turner Motorsport and BMW M works
driver Robby Foley (USA) narrowly missed out on the podium, finishing
fourth – just half a second behind third place – in the two-hour race.

—

IMSA VP Racing SportsCar Challenge (11th to 13th July):
Victory for Jake Walker.

The IMSA VP Racing SportsCar Challenge also took place at
Canadian Tire Motorsport Park. Jake Walker (USA) won the GTDX class in
the #6 BMW M4 GT3 EVO of Turner Motorsport. Samantha Tan (CAN)
finished fourth in the #38 BMW M4 GT3 EVO of ST Racing, which also
secured her victory in the Bronze category.

—

ADAC GT Masters (11th to 13th July): FK Performance Motorsport
narrowly misses podium.

At the ADAC GT Masters race weekend at the Nürburgring (GER),
BMW M Motorsport teams just missed out on the podium. In the second
race, Leyton Fourie (RSA) and Tim Zimmermann (GER) finished fourth in
the #11 BMW M4 GT3 EVO of FK Performance Motorsport. Their teammates
Eduardo Coseteng (PHI) and Julian Hanses (GER) took sixth place. In
the first race, the FK Performance Motorsport crews finished in
seventh and twelfth positions. The Schubert Motorsport duo Sandro and
Juliano Holzem (both GER) finished sixth and eleventh.

—

British GT (11th to 13th July): Century Motorsport celebrates
double podium in Snetterton.

BMW M Motorsport also had reason to celebrate at the British GT
Championship in Snetterton (GBR). On Sunday, Century Motorsport was
unbeatable in the GT4 category: Ravi Ramyead and Charlie Robertson
(both GBR) won in the #71 BMW M4 GT4 EVO, while teammates Branden
Templeton and Chris Salkeld (both GBR) secured third place in the #14
car, completing the double podium for Century Motorsport.

—

GT World Challenge Asia (11th to 13th July): BMW M Motorsport
duo defends championship lead.

At the GT World Challenge Asia powered by AWS race weekend in
Fuji (JPN), Maxime Oosten (NED) and Ruan Cun Fan (CHN) finished third
and seventh in the Sil-Am class in the #89 BMW M4 GT3 EVO from Team
KRC, thereby maintaining their lead in the driver standings for their
class. The PLUS with BMW M Team Studie finished ninth and twelfth in
the Pro-Am category with their #5 BMW M4 GT3 EVO.

—

NLS (5th July): Six class wins for BMW M Motorsport teams.

At the first four-hour race of the Nürburgring Endurance Series
(NLS) on the Nordschleife (GER) following the season highlight 24h
Nürburgring, it was the turn of the smaller classes to shine. In the
absence of GT3 vehicles, BMW M Motorsport customer teams secured six
class victories. Plusline Motorsport triumphed in the SP8T category
with the BMW M4 GT4 EVO. Additional victories came in the BMW 325i,
BMW M2 CS, BMW M240i, SP4, and VT3 classes.

Continue Reading

July 15, 2025
As Trump turns toward Ukraine, Russians wonder if an opportunity was missed – The Washington Post
1. As Trump turns toward Ukraine, Russians wonder if an opportunity was missed The Washington Post
2. I’m ‘disappointed but not done’ with Putin, Trump tells BBC BBC
3. Russia-Ukraine war live: Kremlin needs time to ‘analyse’ Trump’s rhetoric Al Jazeera
4. Slovakia blocks EU move to impose new sanctions package on Russia – Europe live The Guardian
5. Kremlin reacts icily to Trump but some Russian officials are blunter Reuters
Continue Reading
July 15, 2025
Lung Cancer Research Foundation Adds $3.75 Million in Research Funding Opportunities

Through direct donor funding and research collaborations, LCRF strengthens commitment to research

NEW YORK, July 15, 2025 /PRNewswire/ — The Lung Cancer Research Foundation recently announced several new funding opportunities in addition to its normal RFP cycle that began in January. In June, Requests for Proposals were made available for submission for two new Team Science awards and an Early Career Investigator award, providing the research community with more opportunities to advance lung cancer research.

Research is our True North

The 2025 LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers, a 3-year, $1.5 million award, made possible by a generous private donation from Benay and Steven Taub, will focus on furthering the development of novel therapies for patients with EGFR-mutant Non-Small Cell Lung Cancer (NSCLC.)

A research collaboration with Boehringer Ingelheim, totaling $2.25 million, will provide funding for two other grant awards. The LCRF|Boehringer Ingelheim Team Science Award on Innovative Approaches Toward the Treatment of HER2-Driven Lung Cancer award, is a $1.5 million, 3-year award focusing on the science behind HER2 mutations as a driver of malignancy and/or the development of novel therapeutic approaches to treat tumors with HER2 mutations. The LCRF|Boehringer Ingelheim Early Career Investigator’s Award on Innovative Approaches Toward the Treatment of HER2-Driven Lung Cancer will fund three, two-year grants focused on the study of HER2 mutant lung cancer, supporting the work of scientists who are early in their independent research careers.

“LCRF was founded twenty years ago to address critical gaps in lung cancer research funding. Today, as the research landscape grows more uncertain, we remain committed to advancing the science by partnering with like-minded individuals and organizations. Private funding is more essential than ever to sustain progress. While we’ve made significant strides in treatment discovery, far too much promising research still goes unfunded,” says Aubrey Rhodes, LCRF’s executive director. “It is through the generosity of people like Benay and Steven Taub, and the vision of collaborators like Boehringer Ingelheim, that we will make an impact for people living with lung cancer. We have been very fortunate to have many incredible partners that make research happen and look forward to continuing to partner with those who believe, as we do, that investing in research now is what will bring breakthroughs to the fore.”

“We believe that supporting scientists to pursue their curiosity is key to driving meaningful progress and innovation—and that collaboration is essential to bringing groundbreaking treatments to patients,” said Bjoern Rueter, U.S. Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim. “We are excited to join forces with Lung Cancer Research Foundation as we embark on a new era for cancer research and create the Team Science and Early Career Investigator awards focused on HER2-mutant lung cancer.”

“Now more than ever, it is important for organizations like LCRF to fill funding gaps,” says Kathryn O’Donnell, PhD, Chair of LCRF’s Scientific Advisory Board, and Associate Professor of Molecular Biology at UT Southwestern Medical Center. “Partnerships and collaborations across the lung cancer community will allow LCRF’s research program to address unmet needs for researchers, their labs, and all people affected by lung cancer who look to LCRF to fund innovative projects. These efforts will ultimately lead to breakthrough discoveries and new therapies.”

Benay Taub, a lung cancer survivor, was very direct. “Our goal in funding the Team Science Award focused on EGFR lung cancers is to support a team of committed researchers in pursuit of improved treatments and outcomes for lung cancer patients, and hopefully, one day, a cure.”

To learn how you can support LCRF’s research grant program and keep science moving forward, visit LCRF.org/research.

About the Lung Cancer Research Foundation (LCRF)

The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 429 research grants, totaling nearly $48 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information about the LCRF grant program and funding opportunities, visit lcrf.org/research.

Contact:
Sheila Sullivan
Sr. Director, Marketing & Communications, LCRF
[email protected]

SOURCE Lung Cancer Research Foundation

Continue Reading

July 15, 2025